EC
CSTL icon

EntryPoint Capital’s Castle Biosciences CSTL Stock Holding History

EntryPoint Capital’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,432
Closed -$409K – 655
2025
Q1 		$409K Sell
20,432
-8,712
-30% -$216K 0.19% 181
2024
Q4 		$777K Buy
29,144
+19,862
+214% +$605K 0.33% 14
2024
Q3 		$265K Buy
+9,282
New +$236K 0.15% 303

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

EntryPoint Capital's CSTL Position: Q2 2025 in Review

EntryPoint Capital sold out of Castle Biosciences (CSTL) in Q2 2025, closing a stake of 20,432 shares — an estimated $409K sold.

EntryPoint Capital first reported a position in CSTL in Q3 2024 and held it in 3 quarters. The position peaked at $777K in Q4 2024. 152 funds tracked by Wall St. Rank hold CSTL as of Q2 2025.

  • EntryPoint Capital reported no remaining Castle Biosciences position as of Q2 2025 after selling out during the quarter.
  • EntryPoint Capital sold 20,432 Castle Biosciences shares in Q2 2025, an estimated $409K.
  • EntryPoint Capital first reported a position in Castle Biosciences in Q3 2024 and held it in 3 quarters.
  • EntryPoint Capital's Castle Biosciences position peaked at $777K in Q4 2024.
  • 152 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2025.

Based on EntryPoint Capital's 13F filing for Q2 2025, filed 11 Aug 2025.